Internal Medicine, Hematology & Oncology · Harlingen, TX
NPI
1811098304
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2121 Pease St Ste 101
Harlingen, TX, 78550
Phone (956) 425-8845
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
96,286 services
Medicare patients, 2024
633
Average age 74
Drug cost, 2024
$7.3M
2,228 prescriptions
Company payments, 2025
$836
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nabeel Sarhill was code J1756 (injection, iron sucrose, 1 mg), 23,700 times for 28 patients. In total Nabeel Sarhill billed 96,286 services in 143 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1756 Injection, iron sucrose, 1 mg | Office | 23,700 | 28 | $0.18 | $4,180 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 8,100 | 18 | $0.11 | $894 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 4,410 | 12 | $2.29 | $10K |
| J0897 Injection, denosumab, 1 mg | Office | 2,220 | 23 | $20.50 | $46K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2,200 | 21 | $0.10 | $219 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,000 | 18 | $5.78 | $12K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,105 | 37 | $0.09 | $99.43 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,100 | 11 | $16.30 | $18K |
| 85025 Blood Count | Office | 1,025 | 399 | $7.59 | $7,776 |
| 36415 Venipuncture Blood Collection | Office | 918 | 352 | $8.64 | $7,932 |
| 80053 Clinical Chemistry | Office | 826 | 396 | $10.32 | $8,526 |
| 99214 Office E&M - Established | Office | 721 | 382 | $86.98 | $63K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 690 | 20 | $0.77 | $528 |
| 99232 Hospital E&M - Subsequent | Facility | 580 | 158 | $57.14 | $33K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 360 | 11 | $0.27 | $96.24 |
By year: 2022 $1.7M for 104,096 services; 2023 $1.4M for 115,312 services; 2024 $1.2M for 96,286 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,025 | 399 | $7.59 | $7,776 |
| 36415 Venipuncture Blood Collection | 918 | 352 | $8.64 | $7,932 |
| 80053 Clinical Chemistry | 826 | 396 | $10.32 | $8,526 |
| 82728 Clinical Chemistry | 152 | 95 | $13.27 | $2,017 |
| 83540 Clinical Chemistry | 152 | 95 | $6.34 | $964 |
| 83550 Clinical Chemistry | 152 | 95 | $8.51 | $1,294 |
| 85055 Blood Count | 72 | 47 | $35.03 | $2,522 |
| 85027 Blood Count | 64 | 30 | $6.34 | $406 |
| 85007 Blood Count | 63 | 30 | $3.72 | $234 |
| 84153 Clinical Chemistry | 22 | 16 | $18.02 | $396 |
Medicare prescription drug claims, 2024
In 2024, the drug Nabeel Sarhill prescribed most often to Medicare patients was Exemestane, with 241 prescriptions and refills. In total Nabeel Sarhill wrote 2,228 Medicare prescriptions that cost $7.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Exemestane Generic | 241 | 528 | 59 | $34K |
| Dexamethasone Generic | 177 | 184 | 54 | $2,840 |
| Revlimid Lenalidomide | 144 | 144 | 17 | $2.4M |
| Ondansetron Hcl Generic | 140 | 140 | 68 | $1,470 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 125 | 125 | 57 | $2,054 |
| Tamoxifen Citrate Generic | 98 | 198 | 29 | $2,177 |
| Eliquis Apixaban | 83 | 105 | 16 | $60K |
| Letrozole Generic | 65 | 174 | 25 | $1,854 |
| Fentanyl Generic | 59 | 59 | 20 | $7,599 |
| Olanzapine Generic | 57 | 66 | 32 | $237 |
| Hydroxyurea Generic | 47 | 98 | 12 | $792 |
| Tramadol Hcl Generic | 43 | 43 | 16 | $197 |
| Morphine Sulfate Generic | 37 | 37 | 13 | $910 |
| Ondansetron Odt Ondansetron | 35 | 35 | 17 | $393 |
| Imatinib Mesylate Generic | 34 | 34 | Under 11 | $91K |
Brand drugs: 566 claims; generic drugs: 1,662 claims; opioid claims: 272.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nabeel Sarhill $836 ($836 in general payments such as food, travel and fees) from 20 companies. The largest payer was Boston Scientific Corporation with $138.
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation BSX | 1 | $138 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $95.95 |
| Daiichi Sankyo Inc. 4568.T | 3 | $75.68 |
| Eisai Inc. 4523.T | 3 | $67.6 |
| Gilead Sciences, Inc. GILD | 3 | $52.85 |
| Celgene Corporation BMY | 2 | $49.07 |
| Janssen Biotech, Inc. JNJ | 2 | $47.06 |
| Merck Sharp & Dohme LLC MRK | 2 | $45.68 |
| Astellas Pharma US Inc 4503.T | 2 | $39.59 |
| GlaxoSmithKline, LLC. GSK | 2 | $33.46 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.